NPR: What It Was Like To Participate In The Clinical Trial For Moderna’s COVID-19 Vaccine

78

John Yang volunteered to participate in the phase 3 Moderna COVID-19 vaccine trial. The Moderna vaccine has been 94.5% effective and is waiting FDA approval. Yang chose to take part in the trial because he is considered high risk and would rather have the vaccine sooner rather than later. He received two shots, with one month separating them. The primary side effect was fatigue but Yang didn’t know know if he received the vaccine or the placebo. Click here to read more about COVID-19 vaccines. Click here to read the full article by Christianna Silva and Mary Louise Kelly. 

Comments are closed.

Skip to toolbar